Ftse Mib
33.770,05
0,07%
DAX
17.896,50
-0,14%
S&P 500
5.061,36
0,86%
NASDAQ
15.823,91
1,40%
Bitcoin
59.239,97
1,72%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Revance Therapeutics Inc (RVNC) Revance Therapeutics Inc (RVNC) Notizie

Revance Therapeutics Inc

RVNC
3,76
-0,035 (-0,92%)
Ultimo aggiornamento: 21:44:14
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/4/202414:00BWRevance to Present New DAXXIFY® Data at the American Academy..
27/3/202421:05BWRevance Reports Inducement Grants Under Nasdaq Listing Rule..
08/3/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:08EDGAR2Form 8-K - Current report
05/3/202423:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202423:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202415:25BWRevance Announces Pricing of $100.0 Million Public Offering..
04/3/202412:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202412:37BWRevance Announces Proposed Public Offering of Common Stock
29/2/202422:36EDGAR2Form 3 - Initial statement of beneficial ownership of..
28/2/202422:07EDGAR2Form 8-K - Current report
28/2/202422:05BWRevance Reports Fourth Quarter and Full Year 2023 Financial..
21/2/202414:01BWRevance to Release Fourth Quarter and Full Year 2023..
21/2/202414:00BWRevance to Participate in Upcoming Investor Conferences
14/2/202421:45EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202422:28EDGAR2Form 8-K - Current report
13/2/202415:39EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202422:04EDGAR2Form 8-K - Current report
02/2/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202414:00BWRevance Receives Permanent J-Code for DAXXIFY® and Announces..
01/2/202414:00BWRevance to Participate in the Guggenheim 6th Annual..
11/1/202412:18IHMARKETNEWSWall Street Highlights: Mastercard’s Financial Rise,..
08/1/202414:01EDGAR2Form 8-K - Current report
08/1/202414:00BWRevance Provides Corporate Update, Preliminary Fourth..
03/1/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202322:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:04EDGAR2Form 8-K - Current report
12/12/202311:50IHMARKETNEWSHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic..
14/11/202322:22EDGAR2Form S-3ASR - Automatic shelf registration statement of..
08/11/202322:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:09EDGAR2Form 8-K - Current report
08/11/202322:06BWRevance Reports Third Quarter 2023 Financial Results,..
08/11/202322:05BWRevance Appoints Erica Jordan as Chief Commercial Officer,..
06/11/202314:00BWRevance to Participate in Upcoming Investor Conferences
01/11/202313:00BWRevance to Release Third Quarter 2023 Financial Results on..
26/10/202314:00BWDAXXIFY® Becomes First Facial Injectable to be Named to..
24/10/202322:05EDGAR2Form SC 13D/A - General statement of acquisition of..
19/9/202315:01EDGAR2Form 8-K - Current report
19/9/202315:00BWRevance Provides Corporate Update at Investor Day
07/9/202323:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202322:21EDGAR2Form 144 - Report of proposed sale of securities
05/9/202323:43EDGAR2Form 144 - Report of proposed sale of securities
01/9/202315:12EDGAR2Form SC 13D - General statement of acquisition of beneficial..
Apertura: 3,91 Min: 3,655 Max: 3,99
Chiusura: 3,795

La tua Cronologia

NASDAQ
RVNC
Revance Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network